Aşılar, Aşılama, Enfeksiyonlar
Özet
Kanser, dünya genelinde önemli bir sağlık sorunu olup, tedavi süreçleri hastalar için büyük zorluklar yaratmaktadır. Dünya Sağlık Örgütü’ne (WHO) göre, kanser, her yıl milyonlarca insanı etkilemektedir. Kanser tedavisi sırasında bağışıklık sistemi zayıflar, bu da hastaların enfeksiyonlara daha duyarlı hale gelmesine neden olur. Bu nedenle, kanser hastalarında aşılama ve enfeksiyonların yönetimi büyük önem taşır.
Cancer is a significant global health issue, and its treatment processes pose considerable challenges for patients. According to the World Health Organization (WHO), cancer affects millions of people worldwide each year. During cancer treatment, the immune system weakens, making patients more susceptible to infections. Therefore, vaccination and infection management in cancer patients are of great importance.
Referanslar
Sutton SH: Infections associated with solid malignancies. Cancer Treat Res 161:371-411, 2014
Seo SK, Liu C, Dadwal SS: Infectious disease complications in patients with cancer. Crit Care Clin 37:69-84, 2021
Wumkes ML, van der Velden AM, Los M, et al: Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours. Vaccine 31:6177-6184, 2013
Rubin LG, Levin MJ, Ljungman P, et al: 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58:309-318, 2014
Christine Robin a b, Florence Beckerich a b, Catherine Cordonnier a b Immunization in cancer patients: Where we stand Pharmacological Research Volume 92, February 2015, Pages 23-30
Zembower TR: Epidemiology of infections in cancer patients. Cancer Treat Res 161:43-89, 2014
Sutton SH: Infections associated with solid malignancies. Cancer Treat Res 161:371-411, 2014
Bitterman R, Eliakim-Raz N, Vinograd I, et al: Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst Rev 2:Cd008983, 2018
DiazGranados CA, Dunning AJ, Kimmel M, et al: Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 371:635-645, 2014
Essink B, Fierro C, Rosen J, et al: Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults. Vaccine 38:242-250, 2020
Keam B, Kim MK, Choi Y, et al: Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles. Cancer 123:841-848, 2017
Best AF, Bowman M, Li J, et al: COVID-19 severity by vaccination status in the NCI COVID-19 and Cancer Patients Study (NCCAPS). J Natl Cancer Inst 115:597-600, 2023
Leuva H, Zhou M, Brau N, et al: Influence of cancer on COVID-19 incidence, outcomes, and vaccine effectiveness: A prospective cohort study of U.S. veterans. Semin Oncol 49:363-370, 2022
Kobayashi M, Leidner AJ, Gierke R, et al. Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. MMWR Morb Mortal Wkly Rep 2024; 73:793.
Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol 2018; 36:3043.
Best AF, Bowman M, Li J, et al: COVID-19 severity by vaccination status in the NCI COVID-19 and Cancer Patients Study (NCCAPS). J Natl Cancer Inst 115:597-600, 2023
Cortellini A, Tabernero J, Mukherjee U, et al: SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: Results from the OnCovid registry. Lancet Oncol 24:335-346, 2023
Gong IY, Vijenthira A, Powis M, et al: Association of COVID-19 vaccination with breakthrough infections and complications in patients with cancer. JAMA Oncol 9:386-394, 2023
Kimura M, Ferreira VH, Kothari S, et al: Safety and immunogenicity after a three-dose SARS-CoV-2 vaccine schedule in allogeneic stem cell transplant recipients. Transplant Cell Ther 28: 706.e1-706.e10, 2022
Centers for Disease Control and Prevention: Immunization Schedules. Adult Immunization Schedule by Medical Condition and Other Indication. Recommendations for Ages 19 Years or Older, United States, 2024.
Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:109.
Chiou WY, Lee MS, Hung SK, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine on elderly long-term cancer survivors: a population-based propensity score matched cohort study. BMJ Open 2018; 8:e019364.
Andersen MA, Niemann CU, Rostgaard K, et al. Differences and Temporal Changes in Risk of Invasive Pneumococcal Disease in Adults with Hematological Malignancies: Results from a Nationwide 16-Year Cohort Study. Clin Infect Dis 2021; 72:463.
Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep 2020; 69:1.
Baumrin E, Izaguirre NE, Bausk B, et al: Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantation. Blood Adv 5:1585-1593, 2021
Choi JH, Correia de Sousa J, Fletcher M, Gabutti G, Harrington L, Holden M, Kim H, Michel JP, Mukherjee P, Nolan T, Welte T, Maggi S. Improving vaccination rates in older adults and at-risk groups: focus on pertussis. Aging Clin Exp Res. 2022 Jan;34(1)
Conrad A, Perry M, Langlois ME, et al: Efficacy and safety of revaccination against tetanus, diphtheria, Haemophilus influenzae type b and hepatitis B virus in a prospective cohort of adult recipients of allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 26:1729-1737, 2020
Shenoy B, Andani A, Kolhapure S, Agrawal A, Mazumdar J. Endemicity change of hepatitis A infection necessitates vaccination in food handlers: An Indian perspective. Hum Vaccin Immunother. 2022 Dec 31;18
Weng MK, Doshani M, Khan MA, et al: Universal Hepatitis B Vaccination in Adults Aged 19-59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep 71:477-483, 2022
Hwang JP, Feld JJ, Hammond SP, et al: Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol 38: 3698-3715, 2020
Singh J, Stoitsova S, Zakrzewska K, et al: Healthcare-associated hepatitis B and C transmission to patients in the EU/EEA and UK: A systematic review of reported outbreaks between 2006 and 2021. BMC Public Health 22:2260, 2022
Payne AB, Watts JA, Mitchell PK, et al. Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. Lancet 2024; 404:1547.
Castellino SM, Allen KE, Pleasant K, et al: Suboptimal uptake of human papillomavirus (HPV) vaccine in survivors of childhood and adolescent and young adult (AYA) cancer. J Cancer Surviv 13: 730-738, 2019
Hansson E, Forbes HJ, Langan SM, et al: Herpes zoster risk after 21 specific cancers: Population-based case-control study. Br J Cancer 116:1643-1651, 2017
Stadtmauer EA, Sullivan KM, El Idrissi M, et al: Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: Polyfunctional immune responses and lessons for clinical practice. Hum Vaccin Immunother 17:4144-4154, 2021
Dagnew AF, Ilhan O, Lee WS, et al: Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: A phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis 19:988-1000, 2019
Costa E, Buxton J, Brown J, et al. Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient. BMJ Case Rep 2016; 2016.
Weng MK, Doshani M, Khan MA, et al: Universal Hepatitis B Vaccination in Adults Aged 19-59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep 71:477-483, 2022
McLean HQ, Fiebelkorn AP, Temte JL, et al. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62:1
Tenforde MW, Patel MM, Gaglani M, et al: Effectiveness of a third dose of Pfizer-BioNTech and Moderna vaccines in preventing COVID-19 hospitalization among immunocompetent and immunocompromised adults—United States, August-December 2021. MMWR Morb Mortal Wkly Rep 71:118-124, 2022
